BEIJING, China–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE (LON:): 688428), a leading biopharmaceutical company announced that the first patient in China has been administered the drug in the Phase 1b on the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib, a highly brain-penetrant and widely active and selective for mutation in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
NSCLC is the predominant subtype of lung cancer and accounts for approximately 85% of all cases. In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.
Furmonertinib has been advanced by ArriVent into global studies in patients with advanced or metastatic NSCLC with EGFR mutations, including exon 20 insertion mutations. It is approved in China as a first-line treatment for adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletion (19DEL) or exon 21 substitution mutations (L858R), where it is under further development for additional indications with Allist Pharmaceuticals (SSE: 688578) which discovered furmonertinib. The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to furmonertinib for the treatment of patients with previously untreated, locally advanced, or metastatic NSCLC with EGFR exon 20 insertion mutations. Furmonertinib is also being evaluated for the treatment of NSCLC patients with EGFR alpha-c P-loop compression (PACC) mutations.
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other anticancer agents. Preliminary efficacy was observed in ICP-189 monotherapy. In the dose-escalation study, the dosage was increased up to 120 mg with no DLT observed and a favorable pharmacokinetic and safety profile was demonstrated.
Dr. Jasmine Cui, co-founder, president and CEO of InnoCare, said: We are excited to see the latest progress in our clinical collaboration with ArriVent. SHP2 inhibitors are ideal for the treatment of solid tumors in combination with various targeted drugs and immunotherapies and are expected to address enormous unmet medical needs. We will accelerate the clinical trial and expect this innovative therapy to benefit more NSCLC patients more quickly.
About InnoCare
InnoCare is a commercial-stage biopharmaceutical company engaged in the discovery, development and commercialization of first-in-class and/or first-in-class medicines for the treatment of cancer and autoimmune diseases with unmet medical need in China and globally. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States. For more information, please visit: http://www.innocarepharma.com.
Forward-Looking Statements
This contains disclosures of certain forward-looking statements. Except for statements of fact, all other statements may be deemed to be forward-looking statements, that is, regarding our or our management’s intentions, plans, beliefs or expectations that will or may occur in the future. Such statements represent assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance and actual results, development and business decisions may not correspond to the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short- and long-term performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328167713/en/
InnoCare
Average
Chunhua Lu
86+10-66609879
chunhua.lu@innocarepharma.com
Investors
86+10-66609999
ir@Innocarepharma.com
Source: InnoCare Pharma